10-Q: Orgenesis Inc. Reports First Quarter 2024 Results Amidst Restructuring and Financial Challenges

Orgenesis Inc. reported its first quarter 2024 results, marked by a net loss, the reconsolidation of Octomera, and ongoing efforts to address financial and listing challenges.

Summary

• Orgenesis Inc. reported a net loss of $10.0 million for the three months ended March 31, 2024, compared to a net loss of $23.4 million for the same period in 2023.
• The company's revenue remained relatively flat at $141,000 for the quarter.
• Cost of revenues decreased significantly to $492,000 from $2.7 million year-over-year, primarily due to reduced activities in the Octomera segment.
• Operating expenses decreased to $8.9 million from $19.6 million year-over-year.
• The company reconsolidated Octomera LLC into its financial statements on January 29, 2024, after previously deconsolidating it in June 2023.
• Orgenesis deconsolidated Orgenesis Biotech Israel Limited (OBI) on February 14, 2024, resulting in a loss of $66,000.
• The company raised approximately $2.3 million through a private placement of common stock and warrants in March 2024.
• As of March 31, 2024, the company had a working capital deficit of $27.1 million.
• The company has a substantial doubt about its ability to continue as a going concern due to its accumulated deficit of $186.4 million and negative operating cash flows of $4.4 million for the quarter.

Sentiment

Score: 2

Explanation: The document indicates significant financial distress, a going concern warning, and potential delisting from Nasdaq, leading to a very negative sentiment.

Positives

• The net loss decreased significantly year-over-year, indicating improved cost management.
• Cost of revenues and operating expenses saw substantial reductions, reflecting cost-cutting measures.
• The company successfully raised $2.3 million through a private placement, providing some additional capital.
• The reconsolidation of Octomera could potentially streamline operations and improve future performance.

Negatives

• The company continues to operate at a loss, with a net loss of $10.0 million for the quarter.
• Revenue remains very low at $141,000, indicating limited commercial traction.
• The company has a significant working capital deficit of $27.1 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is facing potential delisting from Nasdaq due to non-compliance with listing requirements.

Risks

• The company faces significant financial challenges and may not be able to raise sufficient capital to continue operations.
• The company's common stock is at risk of being delisted from the Nasdaq Capital Market.
• The company's operations in Israel could be affected by ongoing geopolitical and military conflicts.
• The company has a material weakness in its internal control over financial reporting.
• The company's ability to generate sustainable positive cash flows is uncertain.

Future Outlook

The company plans to raise additional capital, explore avenues to increase revenue, reduce expenditures, and potentially exchange outstanding loans for securities. However, there is no assurance that the company will be able to raise additional capital on acceptable terms.

Management Comments

• Management has assessed the company's financial condition and concluded that there is substantial doubt about its ability to continue as a going concern.
• Management is planning to raise additional capital to continue operations and repay outstanding loans.
• Management is exploring additional avenues to increase revenues and reduce or delay expenditures.

Industry Context

The company operates in the biotech sector, specifically focusing on cell and gene therapies. The company's POCare model aims to address the high costs and logistical challenges associated with traditional manufacturing of advanced therapies. The company's financial challenges reflect the difficulties faced by many development-stage biotech companies in securing funding and achieving commercial success.

Comparison to Industry Standards

• The company's revenue of $141,000 is significantly lower than that of established biotech companies, which often report revenues in the millions or billions of dollars.
• The company's net loss of $10.0 million is substantial for a company of its size, and it is not uncommon for early-stage biotech companies to operate at a loss while developing their technologies.
• The company's working capital deficit of $27.1 million is a significant concern, as it indicates a lack of short-term financial resources to meet its obligations.
• The company's going concern warning is a serious issue, as it suggests that the company may not be able to continue operating without additional funding.
• Compared to companies like CRISPR Therapeutics or bluebird bio, which are also in the cell and gene therapy space, Orgenesis is at a much earlier stage of development and faces greater financial challenges.

Legal Proceedings

• The company is involved in several legal proceedings, including a claim for royalties, a claim for finders fees, and a claim related to a convertible loan agreement.
• The company is also involved in a legal proceeding related to an unsecured convertible note agreement and a consultation agreement.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential delisting.
• Employees may be affected by potential cost-cutting measures and the company's uncertain future.
• Customers may be concerned about the company's ability to continue providing services.
• Creditors face the risk of not being repaid due to the company's financial difficulties.

Next Steps

• The company will seek a hearing before a Nasdaq Hearings Panel to address the deficiencies and present a plan to regain compliance.
• The company plans to raise additional capital to continue operations and repay outstanding loans.
• The company will explore additional avenues to increase revenues and reduce or delay expenditures.
• The company may exchange some of its outstanding loans and accounts payable for securities of the company.

Key Dates

Keywords

Orgenesis, Cell and Gene Therapies, POCare, Octomera, Financial Results, Going Concern, Nasdaq Delisting, Private Placement, Convertible Loans, Restructuring